Brought to you by 
Purdue, Mundipharma, Infinity in major oncology/pain deal; relationship ends
03 Nov 2016
Executive Summary
Purdue Pharma LP and its European affiliate Mundipharma International have entered into a multi-faceted development and co-commercialization partnership with Infinity Pharmaceuticals (cancer therapeutics). The agreement gives Infinity freedom to work on its pipeline while securing steady cash flow through 2013.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Purdue, Mundipharma, Infinity in major oncology/pain deal; relationship ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice